Gary Gordon - Concepedia

Author

Gary Gordon

Also Known As

G B Gordon, G GORDON, G Gordon, G. B. GORDON, G. B. Gordon, G. GORDON, G. Gordon, G.B. Gordon, GARY B. GORDON, Gary B Gordon

187

Publications

12K

Citations

H-Index

131

Concepts

All Affiliations

Johns Hopkins University The University of Texas MD Anderson Cancer Center Abbott Fund Johns Hopkins Medicine Memorial Sloan Kettering Cancer Center

About

Gary Gordon is an author at Johns Hopkins University specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	41	4.8K
2	Health Sciences	10	10	1.4K
3	Engineering	4	4	294
4	Public Health	4	4	292
5	Natural Sciences	1	1	86

Gary Gordon

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis Gideon Steinbach, Patrick M. Lynch, Robin Phillips, New England Journal of Medicine	2000	2.5K
Celecoxib for the Prevention of Sporadic Colorectal Adenomas Monica M. Bertagnolli, Craig Eagle, Ann G. Zauber, New England Journal of Medicine	2006	1K
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematology	2016	783
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Matthew S. Davids, Andrew W. Roberts, John F. Seymour, Journal of Clinical Oncology ImmunologyPathologyPharmacotherapyFirst-in-human StudyImmunotherapy	2017	737
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis Susan M. Fischer, Herng-Hsang Lo, Gary Gordon, Molecular Carcinogenesis Chemoprevention StrategyChemopreventive ActivityMedicinePhotocarcinogenesisPhototoxicity	1999	404
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Joyce O’Shaughnessy, Gary J. Kelloff, Gary Gordon, PubMed PathologyCancer BiologyTumor BiologyCancer Cell BiologyRadiation Oncology	2002	383
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies Shivaani Kummar, Robert J. Kinders, Martin Gutierrez, Journal of Clinical Oncology	2009	324
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study John F. Seymour, Shuo Ma, Danielle M. Brander, The Lancet Oncology Phase 1BLymphoid NeoplasiaHematological MalignancyMedicineImmunology	2017	321
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Journal of Clinical Oncology	2018	305
Distinguishing right from left colon by the pattern of gene expression. O K Glebov, Luz M. Rodriguez, Kenneth Nakahara, PubMed Functional GenomicsDevelopmental BiologyGene Expression ProfileMedicineGenetics	2003	283

Page 1